Parallax Volatility Advisers, L.P. Akebia Therapeutics, Inc. Transaction History

Parallax Volatility Advisers, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.32 - $0.67 $35,098 - $73,487	109,683 New	109,683 $39,000
Q3 2020 Nov 13, 2020	SELL	$2.39 - $13.08 $14,708 - $80,494	-6,154 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $41,047 - $83,571	6,154 New	6,154 $84,000
Q2 2019 Aug 14, 2019	SELL	$4.1 - $8.05 $56,522 - $110,977	-13,786 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$5.41 - $8.73 $74,582 - $120,351	13,786 New	13,786 $113,000
Q1 2018 May 15, 2018	SELL	$9.53 - $15.68 $65,642 - $108,003	-6,888 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$14.24 - $19.59 $98,085 - $134,935	6,888	6,888 $102,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $438M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.